Literature DB >> 12625150

Comparison of tafenoquine (WR238605) and primaquine in the post-exposure (terminal) prophylaxis of vivax malaria in Australian Defence Force personnel.

Peter Nasveld1, Scott Kitchener, Michael Edstein, Karl Rieckmann.   

Abstract

On return from duty in North Solomons Province (including Bougainville Island), Papua New Guinea, 586 Australian Defence Force personnel received either primaquine (14-d) or tafenoquine (3-d) post-exposure malaria prophylaxis. Within 12 months, 6 of the 214 volunteers receiving primaquine and 7 of 378 receiving tafenoquine had developed vivax malaria. Overall, volunteers preferred the shorter course of tafenoquine.

Entities:  

Mesh：

Substances：

Year:  2002        PMID： 12625150     DOI： 10.1016/s0035-9203(02)90351-2

Source DB:  PubMed          Journal:  Trans R Soc Trop Med Hyg        ISSN： 0035-9203            Impact factor:   2.184


  10 in total

1.  In vitro activity of tafenoquine against the asexual blood stages of Plasmodium falciparum isolates from Gabon, Senegal, and Djibouti.

Authors:  Bruno Pradines; Modeste Mabika Mamfoumbi; Adama Tall; Cheikh Sokhna; Jean-Louis Koeck; Thierry Fusai; Joel Mosnier; Eric Czarnecki; André Spiegel; Jean-François Trape; Maryvonne Kombila; Christophe Rogier
Journal:  Antimicrob Agents Chemother       Date:  2006-09       Impact factor: 5.191

Review 2.  8-Aminoquinoline Therapy for Latent Malaria.

Authors:  J Kevin Baird
Journal:  Clin Microbiol Rev       Date:  2019-07-31       Impact factor: 26.132

3.  Randomized, double-blind study of the safety, tolerability, and efficacy of tafenoquine versus mefloquine for malaria prophylaxis in nonimmune subjects.

Authors:  Peter E Nasveld; Michael D Edstein; Mark Reid; Leonard Brennan; Ivor E Harris; Scott J Kitchener; Peter A Leggat; Philip Pickford; Caron Kerr; Colin Ohrt; William Prescott
Journal:  Antimicrob Agents Chemother       Date:  2009-12-07       Impact factor: 5.191

Review 4.  Modern malaria chemoprophylaxis.

Authors:  G Dennis Shanks; Michael D Edstein
Journal:  Drugs       Date:  2005       Impact factor: 9.546

5.  Population pharmacokinetics of tafenoquine during malaria prophylaxis in healthy subjects.

Authors:  Bruce G Charles; Ann K Miller; Peter E Nasveld; Mark G Reid; Ivor E Harris; Michael D Edstein
Journal:  Antimicrob Agents Chemother       Date:  2007-05-21       Impact factor: 5.191

Review 6.  Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.

Authors:  Senaka Rajapakse; Chaturaka Rodrigo; Sumadhya Deepika Fernando
Journal:  Cochrane Database Syst Rev       Date:  2015-04-29

7.  Clinical development of new prophylactic antimalarial drugs after the 5th Amendment to the Declaration of Helsinki.

Authors:  Geoffrey S Dow; Alan J Magill; Colin Ohrt
Journal:  Ther Clin Risk Manag       Date:  2008-08       Impact factor: 2.423

8.  Tafenoquine for preventing relapse in people with Plasmodium vivax malaria.

Authors:  Chaturaka Rodrigo; Senaka Rajapakse; Deepika Fernando
Journal:  Cochrane Database Syst Rev       Date:  2020-09-06

9.  Assessment of the prophylactic activity and pharmacokinetic profile of oral tafenoquine compared to primaquine for inhibition of liver stage malaria infections.

Authors:  Qigui Li; Michael O'Neil; Lisa Xie; Diana Caridha; Qiang Zeng; Jing Zhang; Brandon Pybus; Mark Hickman; Victor Melendez
Journal:  Malar J       Date:  2014-04-14       Impact factor: 2.979

Review 10.  Tafenoquine and its potential in the treatment and relapse prevention of Plasmodium vivax malaria: the evidence to date.

Authors:  Yehenew A Ebstie; Solomon M Abay; Wondmagegn T Tadesse; Dawit A Ejigu
Journal:  Drug Des Devel Ther       Date:  2016-07-26       Impact factor: 4.162
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.